Back

Estrogen-related receptor gamma is required for normal auditory innervation and is essential for hearing.

Seshadri, S. V.; Ingham, N.; Mackenzie, R. R.; Carlton, A. J.; Johnson, S. L.; Alcock, D.; Bullen, A.; Smith, K. E.; Marcotti, W.; Steel, K. P.; Nolan, L. S.

2026-05-05 neuroscience
10.64898/2026.05.02.722410 bioRxiv
Show abstract

Estrogen-related receptor gamma (ESRRG), an orphan nuclear receptor with structural homology to the classical estrogen receptors, is widely recognised as a key metabolic regulator involved in mitochondrial, synaptic, and ion-homeostatic pathways. Previous clinical studies suggest a link between ESRRG and auditory function; for example, ESRRG has been associated with susceptibility to age-related hearing loss in women and implicated in congenital hearing loss. However, the biological mechanisms by which ESRRG may mediate hearing function remain largely unknown. Here, using a combination of in vivo auditory physiological recordings, immunofluorescence analyses, single hair-cell electrophysiology, and transcriptomic approaches, we characterise the phenotype of a new inner-ear conditional Esrrg knockout (Esrrg-cKO) to investigate the role of Esrrg in the auditory system. We found that Esrrg-cKO mice of both sexes develop early-onset hearing loss, as evidenced by elevated auditory brainstem response thresholds and reduced wave 1 amplitudes from two weeks of age. These auditory deficits arise from a combination of early-onset cochlear neuronal and innervation malformations, together with inner hair cell synaptic defects and delayed myelination that persist into adulthood. Furthermore, distortion product otoacoustic emissions and endocochlear potential recordings are normal in Esrrg-cKO mice, and although sensory hair cells are preserved, IHCs retain immature biophysical properties. These findings are consistent with auditory neuropathy, and together with our comparative transcriptome analyses, indicate that Esrrg is an essential molecular driver of normal cochlear innervation and maturation.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
PLOS Genetics
756 papers in training set
Top 0.7%
12.8%
2
The Journal of Neuroscience
928 papers in training set
Top 1%
10.2%
3
Nature Communications
4913 papers in training set
Top 23%
8.3%
4
eLife
5422 papers in training set
Top 13%
6.4%
5
Nucleic Acids Research
1128 papers in training set
Top 4%
4.9%
6
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 14%
4.9%
7
Scientific Reports
3102 papers in training set
Top 23%
4.9%
50% of probability mass above
8
Disease Models & Mechanisms
119 papers in training set
Top 0.4%
3.9%
9
Human Molecular Genetics
130 papers in training set
Top 0.7%
3.6%
10
JCI Insight
241 papers in training set
Top 2%
2.6%
11
Cell Reports
1338 papers in training set
Top 19%
2.5%
12
eneuro
389 papers in training set
Top 4%
2.1%
13
PLOS ONE
4510 papers in training set
Top 47%
2.1%
14
Frontiers in Molecular Neuroscience
43 papers in training set
Top 0.2%
1.8%
15
iScience
1063 papers in training set
Top 14%
1.7%
16
Brain
154 papers in training set
Top 3%
1.3%
17
Science Advances
1098 papers in training set
Top 23%
1.2%
18
International Journal of Molecular Sciences
453 papers in training set
Top 10%
1.2%
19
Aging Cell
144 papers in training set
Top 3%
1.0%
20
Science
429 papers in training set
Top 18%
0.9%
21
Genetics
225 papers in training set
Top 3%
0.9%
22
Communications Biology
886 papers in training set
Top 18%
0.9%
23
PLOS Biology
408 papers in training set
Top 16%
0.9%
24
EMBO reports
136 papers in training set
Top 6%
0.8%
25
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 9%
0.8%
26
The American Journal of Human Genetics
206 papers in training set
Top 4%
0.8%
27
Journal of Cell Science
353 papers in training set
Top 2%
0.7%
28
Frontiers in Cellular Neuroscience
79 papers in training set
Top 2%
0.7%
29
Cell Death & Disease
126 papers in training set
Top 3%
0.5%
30
Journal of Clinical Investigation
164 papers in training set
Top 8%
0.5%